These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9886892)

  • 1. Hepatocyte growth factor as a potential index of complication in diabetes mellitus.
    Nakamura S; Morishita R; Moriguchi A; Yo Y; Nakamura Y; Hayashi S; Matsumoto K; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    J Hypertens; 1998 Dec; 16(12 Pt 2):2019-26. PubMed ID: 9886892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats.
    Nakano N; Moriguchi A; Morishita R; Kida I; Tomita N; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    Hypertension; 1997 Dec; 30(6):1448-54. PubMed ID: 9403566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension.
    Nakamura S; Moriguchi A; Morishita R; Aoki M; Yo Y; Hayashi S; Nakano N; Katsuya T; Nakata S; Takami S; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    Biochem Biophys Res Commun; 1998 Jan; 242(1):238-43. PubMed ID: 9439642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.
    Nakamura Y; Morishita R; Nakamura S; Aoki M; Moriguchi A; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    Hypertension; 1996 Sep; 28(3):409-13. PubMed ID: 8794825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor (HGF) as a potential index of severity of hypertension.
    Morishita R; Moriguchi A; Higaki J; Ogihara T
    Hypertens Res; 1999 Sep; 22(3):161-7. PubMed ID: 10515437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue.
    Matsumoto K; Morishita R; Tomita N; Moriguchi A; Yamasaki K; Aoki M; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    J Endocrinol; 2002 Oct; 175(1):217-23. PubMed ID: 12379506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats.
    Matsumoto K; Morishita R; Tomita N; Moriguchi A; Komai N; Aoki M; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    Heart Vessels; 2003 Mar; 18(1):18-25. PubMed ID: 12644877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes.
    Satani K; Konya H; Hamaguchi T; Umehara A; Katsuno T; Ishikawa T; Kohri K; Hasegawa Y; Suehiro A; Kakishita E; Namba M
    Diabet Med; 2006 Jun; 23(6):617-22. PubMed ID: 16759302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor exerts beneficial effects on mice with type II diabetes‑induced chronic renal failure via the NF‑κB pathway.
    Cheng G; Tang X; Zhang J
    Mol Med Rep; 2018 Sep; 18(3):3389-3396. PubMed ID: 30066918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study.
    Simó R; Vidal MT; García-Arumí J; Carrasco E; García-Ramírez M; Segura RM; Hernández C
    Diabetes Res Clin Pract; 2006 Jan; 71(1):36-44. PubMed ID: 16029908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus.
    Kulseng B; Børset M; Espevik T; Sundan A
    Acta Diabetol; 1998 Jul; 35(2):77-80. PubMed ID: 9747958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor levels are associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in patients with type 2 diabetes mellitus.
    Anan F; Masaki T; Yonemochi H; Takahashi N; Nakagawa M; Eshima N; Saikawa T; Yoshimatsu H
    Metabolism; 2009 Feb; 58(2):167-73. PubMed ID: 19154948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control.
    Sözmen B; Delen Y; Girgin FK; Sözmen EY
    Clin Biochem; 1999 Aug; 32(6):423-7. PubMed ID: 10667477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy.
    Shahid SM; Nawab SN; Shaikh R; Mahboob T
    Pak J Pharm Sci; 2012 Jan; 25(1):123-9. PubMed ID: 22186319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension.
    Cipriani R; Sensi M; Gabriele A; Gatti A; Mandosi E; Di Mario U; Morano S
    Diabetes Nutr Metab; 2004 Apr; 17(2):90-4. PubMed ID: 15244100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte growth factor is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients.
    Anan F; Masaki T; Jikumaru K; Iwao T; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2010 Jul; 40(7):585-90. PubMed ID: 20497462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating endothelial cells and hepatocyte growth factor in patients with pregnancy induced hypertension].
    Wang Y; Shang T; Tang WW
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jan; 39(1):18-20. PubMed ID: 14989981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients.
    Komai N; Ohishi M; Morishita R; Moriguchi A; Kaibe M; Matsumoto K; Rakugi H; Higaki J; Ogihara T
    Am J Hypertens; 2002 Jun; 15(6):499-506. PubMed ID: 12074350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain natriuretic polypeptide in type 2 NIDDM patients with albuminuria.
    Nagai T; Imamura M; Inukai T; Mori M
    J Med; 2001; 32(3-4):169-80. PubMed ID: 11563815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women.
    Tamama K; Sumino H; Ichikawa S; Kanda T; Kotajima N; Fukumura Y; Kurabayashi M; Murakami M
    J Hypertens; 2003 Jun; 21(6):1151-6. PubMed ID: 12777952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.